Keating Financial Advisory Services, Inc.
Position in EXEL — Exelixis, Inc.
CIK 2103443
MANHATTAN, KS
Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$581,502
-$2,276,389 QoQ
Shares Held
13,558
-79.2% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Keating Financial Advisory Services, Inc. holds $1,629,151 across 110 Biotechnology names. EXEL ranks #1 (35.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
13,558 | $581,502 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
416 | $185,760 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
223 | $172,298 | |
| 4 | DYN |
Dyne Therapeutics, Inc.
|
5,093 | $92,336 | |
| 5 | ACHV |
Achieve Life Sciences, Inc.
|
24,911 | $73,238 | |
| 6 | VKTX |
Viking Therapeutics, Inc.
|
2,069 | $67,325 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
930 | $52,535 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
127 | $42,020 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $581,502 | 13,558 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,857,891 | 65,204 | Shares | Sole | 2026-02-09 | |
| No filing history on record for this holder in this stock. | ||||||